Patents by Inventor Ella Ioffe
Ella Ioffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240316361Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: ApplicationFiled: April 24, 2024Publication date: September 26, 2024Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 12024570Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: October 14, 2020Date of Patent: July 2, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson
-
Publication number: 20240166740Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: May 15, 2023Publication date: May 23, 2024Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON
-
Publication number: 20240138384Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).Type: ApplicationFiled: January 16, 2024Publication date: May 2, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
-
Patent number: 11910788Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).Type: GrantFiled: January 29, 2021Date of Patent: February 27, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
-
Publication number: 20230279070Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.Type: ApplicationFiled: April 28, 2023Publication date: September 7, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS
-
Publication number: 20230235089Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to immunomodulatory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.Type: ApplicationFiled: November 23, 2022Publication date: July 27, 2023Inventors: Ella Ioffe, Elena Burova
-
Patent number: 11692032Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: June 6, 2019Date of Patent: July 4, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
-
Patent number: 11673930Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy. IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.Type: GrantFiled: May 11, 2021Date of Patent: June 13, 2023Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Jie Dai, Maria del Pilar Molina-Portela, Ella Ioffe, Markus Mohrs
-
Publication number: 20210380702Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: August 11, 2021Publication date: December 9, 2021Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Publication number: 20210355184Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.Type: ApplicationFiled: May 11, 2021Publication date: November 18, 2021Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS
-
Patent number: 11117970Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: February 26, 2018Date of Patent: September 14, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Publication number: 20210161112Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).Type: ApplicationFiled: January 29, 2021Publication date: June 3, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
-
Patent number: 10939673Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).Type: GrantFiled: May 17, 2018Date of Patent: March 9, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
-
Publication number: 20210040232Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: October 14, 2020Publication date: February 11, 2021Inventors: Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON, William OLSON
-
Patent number: 10844137Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: July 26, 2018Date of Patent: November 24, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson
-
Publication number: 20200330794Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: ApplicationFiled: July 2, 2020Publication date: October 22, 2020Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 10737113Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: GrantFiled: February 26, 2018Date of Patent: August 11, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 10532096Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.Type: GrantFiled: April 23, 2018Date of Patent: January 14, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ella Ioffe, Israel Lowy, Gavin Thurston, Elena Burova
-
Publication number: 20190284277Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: June 6, 2019Publication date: September 19, 2019Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON